Ticker HubNYSE

ANVS

Annovis Bio, Inc.

PHARMACEUTICAL PREPARATIONSLatest afterhours mover

Latest price

$0.9601+43.53%

As of Nov 6, 2026, 8:00 PM EST · Market data by Massive

Market cap

$28.8M

Volume

11.7M

Previous close

$0.6689

Day range

$0.6301 – $0.8527

Listed

Jan 29, 2020

Coverage

0 articles

Price performance

Recent trading

5 trading days · 15-minute intervals · ET

Five-day open $1.17Latest interval $0.9601

Newsroom

Latest ANVS coverage

No matching articles yet.

Recent catalyst headlines

Annovis Announces Pricing of $21.0 Million Public Offering

Nov 5, 2026

Annovis Announces Launch of Proposed Public Offering

Nov 4, 2026

Annovis Bio, Inc. Receives Continued Listing Standard Notice from the NYSE

Oct 30, 2026

Company overview

Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.

Industry: PHARMACEUTICAL PREPARATIONS
Employees: 7
Headquarters: MALVERN, PA
CIK: 0001477845

Company website View advanced chart

SEC filings

No filing records are attached to this profile yet.

Browse EDGAR

Profile at a glance

Jan 29, 2020

Listed

Employees

Market data may be delayed and is provided for informational purposes only. SmallCapsDaily content is not investment advice.